C Champions Oncology Inc
C
Suletud
SektorTervishoid
6.13 -1.13
Ülevaade
Aktsiahinna muutus
24h
Min
6.08
Max
6.32
Sissetulek | -514K -278K |
|---|---|
Müük | 1.5M 17M |
P/E Sektori keskmine | 35.118 51.415 |
Aktsiakasum | -0.02 |
Kasumimarginaal | -1.679 |
Töötajad | 213 |
EBITDA | -458K 154K |
Järgmine tulemuste avaldamine | 22. juuli 2026 |
|---|
Turukapital | 558K 83M |
|---|---|
Eelmine avamishind | 7.26 |
Eelmine sulgemishind | 6.13 |
Uudiste sentiment
By Acuity
50%
50%
155 / 345 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Champions Oncology Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Champions Oncology Inc Prognoos
Sentiment
By Acuity
155 / 345 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.